Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Aug;118(8):1939–1944. doi: 10.1111/j.1476-5381.1996.tb15628.x

Effects of RP 73401, a novel, potent and selective phosphodiesterase type 4 inhibitor, on contractility of human, isolated bronchial muscle.

E Naline 1, Y Qian 1, C Advenier 1, D Raeburn 1, J A Karlsson 1
PMCID: PMC1909861  PMID: 8864527

Abstract

1. The aim of this study was to investigate the smooth muscle relaxant effects of the novel, selective phosphodiesterase (PDE) type 4 inhibitor, RP 73401 in comparison with the classical PDE 4 inhibitor, rolipram, the non-selective PDE inhibitor, theophylline and the beta-adrenoceptor agonist, isoprenaline on the human, isolated bronchus. 2. At resting tone, the rank order of potency (pD2) for the relaxants was RP 73401 > or = rolipram > or = isoprenaline >> theophylline. In terms of maximum relaxation produced (Emax) the PDE 4-selective inhibitors were similar, but the maximal effects (70-75% of theophylline, 3 mM) were lower than that observed with isoprenaline (98% of theophylline, 3 mM) or theophylline itself (100%). 3. On the human isolated bronchus pre-contracted with acetylcholine (ACh, 0.1 or 1.0 mM), the rank order of potency remained the same. The maximal responses to RP 73401 and rolipram were however markedly reduced (Emax 39.9-46.6%) compared with isoprenaline (Emax 79-85%). 4. In tissues pre-contracted with ACh (0.1 mM), RP 73401 and rolipram (10(-9)-10(-7) M) significantly and concentration-dependently increased tissue sensitivity to isoprenaline. RP 73401 and rolipram were similar in potency. Both selective PDE 4 inhibitors also significantly increased the maximal relaxant effects of isoprenaline. These effects were not observed with the PDE 3 inhibitor, siguazodan. 5. In terms of retention by tissues (an index of duration of action), the onset of action of RP 73401 (2.11 +/- 0.53 min) and rolipram (1.70 +/- 0.45 min) was significantly slower than that of isoprenaline (0.33 +/- 0.06 min) or theophylline (1.17 +/- 0.25 min). The retention of RP 73401 (89.0 +/- 21.9 min) on the human isolated bronchial tissues after washing was however dramatically longer than that of rolipram (18.3 +/- 4.5 min), theophylline (3.43 +/- 0.58 min) or isoprenaline (2.81 +/- 0.31 min). 6. These data indicate that RP 73401 is a potent and long acting relaxant of human bronchial muscle in vitro. RP 73401 is more potent than the classical PDE 4-selective inhibitor rolipram and the non-selective PDE inhibitor theophylline and is retained in bronchial tissue for a much longer period of time.

Full text

PDF
1939

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashton M. J., Cook D. C., Fenton G., Karlsson J. A., Palfreyman M. N., Raeburn D., Ratcliffe A. J., Souness J. E., Thurairatnam S., Vicker N. Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. J Med Chem. 1994 May 27;37(11):1696–1703. doi: 10.1021/jm00037a021. [DOI] [PubMed] [Google Scholar]
  2. Barnes P. J., Pauwels R. A. Theophylline in the management of asthma: time for reappraisal? Eur Respir J. 1994 Mar;7(3):579–591. doi: 10.1183/09031936.94.07030579. [DOI] [PubMed] [Google Scholar]
  3. Cortijo J., Bou J., Beleta J., Cardelús I., Llenas J., Morcillo E., Gristwood R. W. Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br J Pharmacol. 1993 Feb;108(2):562–568. doi: 10.1111/j.1476-5381.1993.tb12841.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fernandes L. B., Fryer A. D., Hirshman C. A. M2 muscarinic receptors inhibit isoproterenol-induced relaxation of canine airway smooth muscle. J Pharmacol Exp Ther. 1992 Jul;262(1):119–126. [PubMed] [Google Scholar]
  5. Jeppsson A. B., Löfdahl C. G., Waldeck B., Widmark E. On the predictive value of experiments in vitro in the evaluation of the effect duration of bronchodilator drugs for local administration. Pulm Pharmacol. 1989;2(2):81–85. doi: 10.1016/0952-0600(89)90028-8. [DOI] [PubMed] [Google Scholar]
  6. Karlsson J. A., Persson C. G. Influence of tracheal contraction on relaxant effects in vitro of theophylline and isoprenaline. Br J Pharmacol. 1981 Sep;74(1):73–79. doi: 10.1111/j.1476-5381.1981.tb09956.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Löfdahl C. G., Chung K. F. Long-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma. Eur Respir J. 1991 Feb;4(2):218–226. [PubMed] [Google Scholar]
  8. Naline E., Zhang Y., Qian Y., Mairon N., Anderson G. P., Grandordy B., Advenier C. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J. 1994 May;7(5):914–920. [PubMed] [Google Scholar]
  9. Nicholson C. D., Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes--their potential utility in the therapy of asthma. Pulm Pharmacol. 1994 Feb;7(1):1–17. doi: 10.1006/pulp.1994.1001. [DOI] [PubMed] [Google Scholar]
  10. Qian Y., Naline E., Karlsson J. A., Raeburn D., Advenier C. Effects of rolipram and siguazodan on the human isolated bronchus and their interaction with isoprenaline and sodium nitroprusside. Br J Pharmacol. 1993 Jul;109(3):774–778. doi: 10.1111/j.1476-5381.1993.tb13641.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rabe K. F., Tenor H., Dent G., Schudt C., Liebig S., Magnussen H. Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. Am J Physiol. 1993 May;264(5 Pt 1):L458–L464. doi: 10.1152/ajplung.1993.264.5.L458. [DOI] [PubMed] [Google Scholar]
  12. Raeburn D., Advenier C. Isoenzyme-selective cyclic nucleotide phosphodiesterase inhibitors: effects on airways smooth muscle. Int J Biochem Cell Biol. 1995 Jan;27(1):29–37. doi: 10.1016/1357-2725(94)00060-3. [DOI] [PubMed] [Google Scholar]
  13. Raeburn D., Underwood S. L., Lewis S. A., Woodman V. R., Battram C. H., Tomkinson A., Sharma S., Jordan R., Souness J. E., Webber S. E. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol. 1994 Dec;113(4):1423–1431. doi: 10.1111/j.1476-5381.1994.tb17156.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Tomkinson A., Karlsson J. A., Raeburn D. Comparison of the effects of selective inhibitors of phosphodiesterase types III and IV in airway smooth muscle with differing beta-adrenoceptor subtypes. Br J Pharmacol. 1993 Jan;108(1):57–61. doi: 10.1111/j.1476-5381.1993.tb13439.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Torphy T. J., Undem B. J., Cieslinski L. B., Luttmann M. A., Reeves M. L., Hay D. W. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J Pharmacol Exp Ther. 1993 Jun;265(3):1213–1223. [PubMed] [Google Scholar]
  16. Ullman A., Bergendal A., Lindén A., Waldeck B., Skoogh B. E., Löfdahl C. G. Onset of action and duration of effect of formoterol and salmeterol compared to salbutamol in isolated guinea pig trachea with or without epithelium. Allergy. 1992 Aug;47(4 Pt 2):384–387. doi: 10.1111/j.1398-9995.1992.tb02076.x. [DOI] [PubMed] [Google Scholar]
  17. Watson N., Eglen R. M. Effects of muscarinic M2 and M3 receptor stimulation and antagonism on responses to isoprenaline of guinea-pig trachea in vitro. Br J Pharmacol. 1994 May;112(1):179–187. doi: 10.1111/j.1476-5381.1994.tb13049.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Watson N., Magnussen H., Rabe K. F. Antagonism of beta-adrenoceptor-mediated relaxations of human bronchial smooth muscle by carbachol. Eur J Pharmacol. 1995 Mar 14;275(3):307–310. doi: 10.1016/0014-2999(95)00048-p. [DOI] [PubMed] [Google Scholar]
  19. de Boer J., Philpott A. J., van Amsterdam R. G., Shahid M., Zaagsma J., Nicholson C. D. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br J Pharmacol. 1992 Aug;106(4):1028–1034. doi: 10.1111/j.1476-5381.1992.tb14451.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES